This review is from the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA): a randomised controlled trial. These studies included almost 7000 patients in 605 centres across 27 countries.
Independent commentary is provided by Associate Professor Neale Cohen, a physician specialising in diabetes and endocrinology, and General Manager of Diabetes Services at the Baker IDI Heart and Diabetes Institute.
Please login below to download this issue (PDF)